Results 191 to 200 of about 2,919,475 (397)

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non‐Thymomatous Myasthenia Gravis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Thymectomy is associated with positive effects on myasthenia gravis (MG), but there is conflicting evidence regarding potential deleterious long‐term outcomes, such as increased cancer and autoimmune disease risk. We aimed to assess these outcomes in thymectomized versus non‐thymectomized MG patients.
Mohamed Khateb, Adnan Almasri, Carolina Barnett‐Tapia, Vera Bril   +3 more
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, EarlyView.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

AKT Signaling Regulates Agrin-Mediated Acetylcholine Receptor Surface Density. [PDF]

Medicina (Kaunas)
Jaiswal N, Lin NR, Lehnen CF, Tariq A, Lukov LL, Zhang C.   +5 more
europepmc   +1 more source

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis (DIG‐MG): A Randomized Controlled Trial of Feasibility, Adherence, and Effects on Fatigue

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Physical activity and sleep influence fatigue in myasthenia gravis (MG), and digital health technologies (DHT) enable objective monitoring of these behaviors in daily life. Using this approach, we evaluated whether a lifestyle intervention targeting physical activity or sleep hygiene could reduce fatigue in MG.
Maja Norling, Niclas Eriksson, Elisabet Westerberg, Ingela Nygren, Klara Norman, Julia Hedberg, Sui H. Wong, Susanna Jernelöv, Pernilla Åsenlöf, Anna Rostedt Punga   +9 more
wiley   +1 more source

Anti-M3 Muscarinic Acetylcholine Receptor Autoantibody in the Serum and Saliva of Oral Lichen Planus Patients: A Case-Control Study. [PDF]

Health Sci Rep
Agha-Hosseini F, Koochaki M, Moosavi MS, Mirzaei-Dizgah I, Khayamzadeh M.   +4 more
europepmc   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

A Test–Retest Paradigm of the Forced Swimming Test in Female Mice Is Not Valid for Predicting Antidepressant-Like Activity: Participation of Acetylcholine and Sigma-1 Receptors

, 2013
Jing Su, Noriko Hato-Yamada, Hiroaki Araki, Hiroyuki Yoshimura   +3 more
openalex   +2 more sources

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. [PDF]

Eur J Immunol
Khodadadi L, Puppe D, Cirillo DS, Martinez-Cingolani C, Klotsche J, Pelz A, Kohler S, Cheng Q, Lazaridis K, Fichtner M, Pille J, Kruglov A, Bondareva M, Alexander T, Radbruch A, Meisel A, Hiepe F.   +16 more
europepmc   +1 more source